Artificial Pancreas to Treat Type 1 Diabetes Mellitus
Substitution of diseased organ/tissues with totally artificial machines or transplantable biohybrid devices where functionally competent cells are enveloped within immunoprotective artificial membranes could represent one of the future goals in medicine. In particular, artificial or, closer to feasibility, biohybrid artificial pancreas (BHAP) could replace the function of pancreatic islet β-cells that have been destroyed by autoimmunity, thereby obviating the need to treat patients with type 1 diabetes mellitus (T1DM) with multiple daily insulin injections. State-of-the-art diabetes therapy and perspectives in the use of BHAP, with special regard to islet-cell-containing microcapsules fabricated with alginate-based polymers, including applications to experimental animal models according to different chemical procedures, are reviewed. Special emphasis has been given to preparation methods, immunoprotection strategies, and biocompatibility of the islet-cell-containing microbarriers, as well as to approaches to ameliorate these features. Currently available BHAP prototypes have been critically reviewed to define expectations about the next generation devices targeting the final cure of T1DM.
- Improvements in the Application of Firefly Luciferase Assays
- 虾酚氧化酶(PO)酶联免疫分析(ELISA)
- Estimation of Chronological Age from the Racemization Rate of l- and d-Aspartic Acid: How to Completely Separate Enantiomers fro
- Qβ复制酶反应
- DNA的凝胶电泳
- 荧光素作为半抗原用于核酸标记探针
- Using Rapid Amplification of cDNA Ends (RACE) to Obtain Full-Length cDNAs
- 分子生物学一线实验人员软件解决方案
- 加糖猕猴桃片
- 质粒载体